IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Bought by Jennison Associates LLC

Jennison Associates LLC lifted its position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 136.6% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 972,266 shares of the company's stock after buying an additional 561,404 shares during the period. Jennison Associates LLC owned approximately 1.15% of IDEAYA Biosciences worth $30,801,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the company. Quest Partners LLC grew its holdings in shares of IDEAYA Biosciences by 2,791.5% during the third quarter. Quest Partners LLC now owns 34,062 shares of the company's stock valued at $1,079,000 after buying an additional 32,884 shares during the last quarter. KBC Group NV lifted its stake in shares of IDEAYA Biosciences by 29.1% in the 3rd quarter. KBC Group NV now owns 2,274 shares of the company's stock valued at $72,000 after purchasing an additional 513 shares during the period. GSA Capital Partners LLP purchased a new stake in IDEAYA Biosciences during the third quarter worth $477,000. Entropy Technologies LP purchased a new stake in IDEAYA Biosciences during the third quarter worth $275,000. Finally, Covestor Ltd raised its position in shares of IDEAYA Biosciences by 23,050.0% in the third quarter. Covestor Ltd now owns 926 shares of the company's stock worth $29,000 after acquiring an additional 922 shares during the period. Institutional investors own 98.29% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on IDYA. Leerink Partners lowered IDEAYA Biosciences from an "outperform" rating to a "market perform" rating and dropped their price objective for the company from $41.00 to $27.00 in a report on Tuesday, November 5th. Wedbush restated an "outperform" rating and set a $52.00 price objective on shares of IDEAYA Biosciences in a research report on Monday, November 4th. Stephens started coverage on shares of IDEAYA Biosciences in a research report on Monday. They set an "overweight" rating and a $51.00 price target on the stock. Oppenheimer reiterated an "outperform" rating and issued a $53.00 price objective on shares of IDEAYA Biosciences in a report on Tuesday, October 29th. Finally, Lifesci Capital upgraded IDEAYA Biosciences to a "strong-buy" rating in a research report on Monday, July 29th. Two investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $53.67.

IDEAYA Biosciences Trading Down 0.2 %

Shares of IDYA traded down $0.04 during mid-day trading on Friday, hitting $26.56. 728,692 shares of the company's stock were exchanged, compared to its average volume of 852,879. The business's 50 day moving average is $30.60 and its two-hundred day moving average is $35.94. The firm has a market capitalization of $2.30 billion, a P/E ratio of -11.58 and a beta of 0.86. IDEAYA Biosciences, Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $47.74.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The company reported ($0.60) EPS for the quarter, beating the consensus estimate of ($0.63) by $0.03. During the same quarter last year, the firm posted ($0.46) earnings per share. On average, equities research analysts forecast that IDEAYA Biosciences, Inc. will post -2.46 earnings per share for the current year.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.